Genotype-guided medical treatment of arteriovenous malformation

S Polubothu^{1

2}

Affiliations

¹ Department of Paediatric Dermatology, Great Ormond Street Children's Hospital NHS Trust, London, UK.
² Mosaicism and Precision Medicine Laboratory, The Francis Crick Institute, London, UK.

S Polubothu. Clin Exp Dermatol. 2021 Jun.

. 2021 Jun;46(4):800-801.

doi: 10.1111/ced.14439. Epub 2021 Mar 21.

S Polubothu^{1

2}

¹ Department of Paediatric Dermatology, Great Ormond Street Children's Hospital NHS Trust, London, UK.
² Mosaicism and Precision Medicine Laboratory, The Francis Crick Institute, London, UK.

No abstract available

References

1. Lekwuttikarn R, Lim YH, Admani S. et al. Genotype-guided medical treatment of an arteriovenous malformation in a child. JAMA Dermatol 2019; 155: 256-7.
1. Lindhurst MJ, Sapp JC, Teer JK et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011; 365: 611-19.
1. Keppler-Noreuil KM, Rios JJ, Parker VE et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 2015; 167a: 287-95.
1. Al-Olabi L, Polubothu S, Dowsett K et al. Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest 2018; 128: 1496-508.
1. Biesecker LG, Edwards M, O'Donnell S et al. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). Cold Spring Harb Mol Case Stud 2020; 6: a004549.